Eris Lifesciences Limited has issued a postal ballot notice seeking member approval for the appointment of Mr. Vineet Varma as an Independent Director of the company. The notice, dated April 23, 2026, has been dispatched in electronic form to all members whose names appear in the Register of Members or Register of Beneficial Owners maintained by NSDL and CDSL as on the cut-off date of April 17, 2026.

The proposed resolution seeks approval for appointing Mr. Vineet Varma (DIN: 11600100) as a Non-Executive and Independent Director for a term of five consecutive years commencing from March 14, 2026, to March 13, 2031. The appointment is subject to the approval of members and follows his initial appointment as an Additional Director. Mr. Varma brings over 25 years of professional experience, having worked with international banks including First Abu Dhabi Bank and ABN Amro Bank across various financial domains.

E-Voting Schedule and Process

The company has facilitated remote e-voting in compliance with the SEBI Listing Regulations and relevant circulars issued by the Ministry of Corporate Affairs and SEBI. The e-voting period is scheduled as follows:

| --- | --- | | Commencement of remote e-voting period | 9.00 A.M. IST on Friday, April 24, 2026 | | Conclusion of remote e-voting period | 5.00 P.M. IST on Saturday, May 23, 2026 | | Cut-off date for eligibility to vote | Friday, April 17, 2026 |

Members can cast their votes electronically through multiple methods including NSDL and CDSL depository facilities, depository participant websites, or directly through the InstaVote platform. The company has engaged MUFG Intime India Private Limited (formerly Link Intime India Private Limited) as the Registrar and Share Transfer Agent to facilitate the e-voting process.

Scrutinizer and Results Declaration

Mr. Ravi Kapoor, a Practicing Company Secretary (FCS No. 2587; COP No 2407) and proprietor of M/s. Ravi Kapoor & Associates, Ahmedabad, has been appointed as the Scrutinizer to conduct the postal ballot process in a fair and transparent manner. The Scrutinizer will submit the results to the Chairman after completion of the scrutiny of e-votes.

The results of the postal ballot along with the Scrutinizer's Report will be displayed on the company's website at https://eris.co.in/ , on the MUFG website at https://instavote.linkintime.co.in/ , and at the Registered Office of the Company on or before Monday, May 25, 2026. The results will be simultaneously communicated to the National Stock Exchange of India Limited and BSE Limited, where the equity shares of the company are listed.

Director Profile and Disclosures

Mr. Vineet Varma has submitted all statutory disclosures and declarations necessary for directorship, including written consent to act as director, confirmation of non-disqualification under Section 164(2) of the Companies Act, 2013, and declaration of meeting independence criteria under Section 149(6) of the Act and SEBI Listing Regulations, 2015. He is an alumnus of the London Business School and Shriram College of Commerce, New Delhi, and has served on the Client Advisory Board of Citibank and Bank of America Merrill Lynch.

The company has received the recommendation of the Nomination and Remuneration Committee for his candidature. The appointment, if approved by members, will be effective from March 14, 2026, and Mr. Varma will not be liable to retire by rotation. He will be entitled to receive sitting fees for attending meetings of the Board and its Committees as determined by the Board from time to time in accordance with applicable laws and company policies.

Eris Lifesciences has received an Outperform rating from Macquarie with a target price of ₹1,680, despite facing regulatory compliance challenges following a HALMED inspection of its Swiss Parenterals manufacturing facilities. The brokerage firm views the regulatory observations as manageable while acknowledging potential delays in the company's EU-focused CDMO expansion plans.

Macquarie's Investment Outlook

Macquarie has maintained its positive stance on Eris Lifesciences, setting a target price of ₹1,680 with an Outperform rating. The brokerage firm considers the HALMED inspection findings as non-material and manageable issues that can be addressed through proper remediation measures.

HALMED Inspection Findings

HALMED, Croatia's Agency for Medicinal Products and Medical Devices, conducted a comprehensive inspection of Swiss Parenterals Ltd.'s manufacturing facilities and identified procedural non-compliance observations. The inspection covered both Unit 1 and Unit 2 facilities in Ahmedabad, Gujarat, revealing deficiencies that require corrective action.

Impact on EU-CDMO Ambitions

The regulatory observations are expected to affect Eris Lifesciences' European contract development and manufacturing organization (CDMO) expansion timeline. While existing business operations face minimal disruption, the compliance issues may delay the commercialization of the EU-CDMO product pipeline and impact export opportunities in the European market.

Remediation Strategy

Eris Lifesciences has outlined a comprehensive remediation plan to address all identified deficiencies. The company will implement corrective and preventive actions (CAPAs) within the stipulated timelines and subsequently request a follow-up inspection from HALMED to verify compliance restoration and resume its European market expansion plans.